Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Payables (2016 - 2025)

Historic Payables for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $45.2 million.

  • Fortress Biotech's Payables fell 2996.64% to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year decrease of 2996.64%. This contributed to the annual value of $65.5 million for FY2024, which is 1095.81% down from last year.
  • Fortress Biotech's Payables amounted to $45.2 million in Q3 2025, which was down 2996.64% from $48.6 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Payables ranged from a high of $108.4 million in Q1 2023 and a low of $44.6 million during Q1 2021
  • Its 5-year average for Payables is $77.2 million, with a median of $76.4 million in 2024.
  • Its Payables has fluctuated over the past 5 years, first crashed by 6266.85% in 2021, then surged by 10443.51% in 2022.
  • Over the past 5 years, Fortress Biotech's Payables (Quarter) stood at $91.5 million in 2021, then increased by 9.75% to $100.4 million in 2022, then decreased by 26.73% to $73.6 million in 2023, then dropped by 10.96% to $65.5 million in 2024, then crashed by 31.04% to $45.2 million in 2025.
  • Its Payables was $45.2 million in Q3 2025, compared to $48.6 million in Q2 2025 and $66.3 million in Q1 2025.